It identifies the key companies involved in creating targeted Ovarian Cancer treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions ...

The increasing usage of an imaging drug, Cytalux, enables surgeons to identify and then remove more, if not all cancer cells ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

Website: www.targetovariancancer.org.uk Helpline: 020 7923 5475 Target Ovarian Cancer: online contact form Email: [email protected] Eve Appeal Information and support for anyone ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.

Epithelial ovarian cancer is the fourth biggest cause of cancer ... including those with emerging target and biological agents.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

Signet Therapeutics ("Signet"), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, today announced that the first patient has been dosed in the ...